# Sermorelin Dosage: The Doses Studied in the Research Record > Sermorelin dosage in the research record: 30 mcg/kg/day subcutaneous at bedtime in pediatric trials, 0.5-1 mg twice daily in older men, and intravenous diagnostic doses — reported, not recommended. What was administered, to which population, by which route, over how long — read from the literature, with no dosing recommendation offered. ## In plain English This page on sermorelin dosage describes the amounts used in published studies — it does not tell anyone what to take. Sermorelin is supplied for laboratory research, not as a medicine to self-administer, so what follows is a record of doses, routes (mostly an injection under the skin), and how long each study ran. In short: children in the efficacy trials got a weight-based dose once nightly; older men in the aging studies got a fixed dose twice a day for two weeks; and a few diagnostic studies used a single dose into a vein. The figures are reported with the study that used them. ## Sermorelin dosage: doses studied in the research record The doses below describe what studies administered, framed as research findings — not instructions, and not a recommendation. Sermorelin is described here as a research peptide; this digest gives no human dosing guidance, and the figures should be read as a log of what investigators did, not as a protocol to follow. The pediatric efficacy work used a single daily subcutaneous dose of 30 mcg/kg/day, given at bedtime [1][7]. The dose is weight-based — micrograms per kilogram of body weight — which is the usual way pediatric endocrine dosing is expressed, and it was delivered once nightly rather than spread across the day. Long-term pediatric dosing at that 30 mcg/kg/day level continued for 12-24 months in one cohort, where GHRH antibodies appeared in some responders without interfering with growth and no changes in glucose or lipids were noted [7]. A comparison study took the question further, dosing prepubertal children at 30 or 60 mcg/kg/day subcutaneously in three daily doses; height velocity was lowest in the low-dose group but, at the high dose, reached a level comparable to growth hormone over six months [10] — a hint that, within the studied range, more GHRH stimulus produced more growth response up to a point. Adult GH-axis research used a different scheme entirely: fixed milligram doses of 0.5 mg and 1 mg subcutaneously twice daily for 14 days in healthy older men, which produced dose-related GH and IGF-1 increases, with the high dose bringing those values in line with young men [2]. Note the contrast in design — weight-based once-nightly dosing in the growth studies, fixed twice-daily dosing in the aging studies — reflecting two different research questions rather than one consensus regimen. Pharmacokinetic and diagnostic studies used intravenous dosing on a much smaller scale: 0.25-2 mcg/kg elicited GH release in healthy men, with 1-2 mcg/kg maximal [3], and a single intravenous bolus near 1 mcg/kg was historically used to probe the pituitary's capacity to release GH — a GH stimulation test [8]. These diagnostic doses are far lower than the therapeutic subcutaneous regimens, because the goal was to read the gland's response, not to sustain an effect. ## Routes studied and formulation notes Subcutaneous injection — an injection into the fat layer just under the skin — is the primary route across the efficacy literature [1][2][7]. Intravenous dosing appears in the diagnostic and pharmacokinetic studies [3][8], where the aim was a precise, immediate blood level for measurement rather than a sustained effect. Intranasal administration was tried historically but performed poorly: bioavailability was only 3-5% [3], meaning the overwhelming majority of an intranasal dose never reached circulation in active form. That low intranasal number matters beyond its own study, because it is consistent with the research-community view that oral, sublingual, and troche "sermorelin" formulations are largely ineffective. Peptides are degraded by digestive enzymes in the gut and absorbed poorly across the mouth's mucous membranes, so a route that has to cross those barriers tends to deliver very little intact peptide — the 3-5% intranasal figure is the closest measured proxy for how steep that penalty is [3]. On handling, lyophilized (freeze-dried) sermorelin acetate is reconstituted with a sterile diluent and, once reconstituted, typically refrigerated; aqueous peptide solutions are prone to degradation, which is why GHRH(1-29) is supplied as a lyophilized powder rather than a ready-made liquid. Compounded preparations are prepared under USP <797> sterile-compounding standards. These are formulation observations drawn from the literature and from compounding practice, not preparation instructions, and nothing here should be read as a how-to. ## Why night-time administration is studied Growth hormone is released mostly in pulses during slow-wave (deep) sleep, so bedtime dosing aligns the stimulus with the body's natural nocturnal GH pulse; the pediatric efficacy trial dosed subcutaneously once daily at bedtime [1]. The logic is to work with the body's clock rather than against it — GHRH itself has a recognized physiologic role in slow-wave sleep, so a bedtime GHRH stimulus arrives when the somatotrophs are already primed to fire. This is a description of the timing investigators used and the rationale they gave, not a protocol recommendation; the digest reports it as a feature of the study design. ## When is sermorelin studied as being administered? Bedtime is the timing used in the literature, because it coincides with the body's natural nocturnal, slow-wave-sleep GH pulse; the pediatric efficacy trial dosed once daily at bedtime subcutaneously [1]. The adult aging studies dosed twice daily over 14 days [2]. This digest reports those timings rather than recommending one. ## How long were studies run? Study durations varied widely. Adult GH/IGF-1 effects were measured over 14 days [2], a GHRH-analog cognition trial ran 20 weeks [6], and pediatric growth trials ran 6 to 24 months [7][10]. This digest reports those windows rather than recommending a course length; "how long is enough" is a clinical question outside its scope. --- A reviewer's reading desk for the Sermorelin record — the GHRH(1-29) pediatric height-velocity, half-life, and adult GH/IGF-1 figures loaded into one window and read straight from the published literature; no clinic behind the screen and nothing here sourced, dispensed, or sold.